Skip to content
10-Q

Quarterly Report

EIKON THERAPEUTICS, INC. EIKN

0001193125-26-216791

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 54.14M sh
Shares Diluted Q1 2026 · Mar 31, 2026 33.7M sh
Shares Diluted Q1 2026 · Mar 31, 2025 2.77M sh
Capex Q1 2026 · Mar 31, 2026 $262K
Capex Q1 2026 · Mar 31, 2025 $22.36M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$89.8M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$54.52M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $161.15M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $104.9M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $204.58M
Stockholders Equity Q1 2026 · Mar 31, 2026 $550.67M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$879.03M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$640.14M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$571.93M
Current Liabilities Q1 2026 · Mar 31, 2026 $45.06M
Current Liabilities Q1 2026 · Dec 31, 2025 $55.01M
Total Liabilities Q1 2026 · Mar 31, 2026 $300.16M
Total Liabilities Q1 2026 · Dec 31, 2025 $312.3M
Current Assets Q1 2026 · Mar 31, 2026 $529.5M
Current Assets Q1 2026 · Dec 31, 2025 $348.92M
Total Assets Q1 2026 · Mar 31, 2026 $850.83M
Total Assets Q1 2026 · Dec 31, 2025 $594.73M
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.46
Eps Diluted Q1 2026 · Mar 31, 2025 −$26.91
Eps Basic Q1 2026 · Mar 31, 2026 −$2.46
Eps Basic Q1 2026 · Mar 31, 2025 −$26.91
Sga Expense Q1 2026 · Mar 31, 2026 $17.29M
Sga Expense Q1 2026 · Mar 31, 2025 $14.8M
Rd Expense Q1 2026 · Mar 31, 2026 $70.05M
Rd Expense Q1 2026 · Mar 31, 2025 $56.59M
Net Income Q1 2026 · Mar 31, 2026 −$82.96M
Net Income Q1 2026 · Mar 31, 2025 −$68.24M
Operating Income Q1 2026 · Mar 31, 2026 −$87.34M
Operating Income Q1 2026 · Mar 31, 2025 −$71.38M